guest ::
| Home > Publications database > Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. > print |
| Home > Publications database > Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. > print |
| 001 | 305583 | ||
| 005 | 20251101115631.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.125.270239 |2 doi |
| 024 | 7 | _ | |a pmid:41167722 |2 pmid |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02242 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Djaileb, Loïc |b 0 |
| 245 | _ | _ | |a Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. |
| 260 | _ | _ | |a New York, NY |c 2025 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1761918027_171915 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub / brief communication |
| 520 | _ | _ | |a Although tumor volume and new lesions (NLs) have been investigated previously as measures of response, the clinical impact of changes in tumor uptake on prostate-specific membrane antigen (PSMA) PET remains largely unknown. Methods: This multicenter retrospective study investigated the clinical impact of changes in tumor uptake and volume on PSMA PET during [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer (mCRPC). The primary outcomes were the associations of changes in SUVmax (ΔSUVmax) and SUVmean (ΔSUVmean), changes in total tumor volume (ΔTTV), and occurrence of NLs with prostate-specific antigen (PSA) progression-free survival (PSA-PFS) and overall survival (OS). The study included patients with mCRPC who received [177Lu]Lu-PSMA between 2014 and 2019. PSMA PET/CT was performed at baseline and after 2 cycles of therapy. Whole-body analyses (SUVmax, SUVmean, TTV, and NLs) were performed and calculated using qPSMA software. Results: In total, 124 patients with mCRPC (median age, 73 y; interquartile range, 67-76 y) were included in the study. Whole-body ΔTTV and the occurrence of NLs were significantly associated with shorter PSA-PFS (hazard ratio [HR], 5.7; 95% CI, 3.59-9.06; and HR, 1.6; 95% CI, 1.4-1.8; P < 0.0001) and with OS (HR, 2.3; 95% CI, 1.61-3.43; and HR, 1.3; 95% CI, 1.1-1.4; P < 0.001). Patient-based analysis showed that ΔSUVmax and ΔSUVmean were not associated with outcome (HR, 1.00; 95% CI, 0.99-1.00; P = 0.30; and HR, 0.90; 95% CI, 0.99-1.00; P = 0.11). Region-based analysis found that only ΔSUVmax in visceral lesions was significantly associated with PSA-PFS (P = 0.007) but not with OS. Conclusion: Only ΔTTV and the occurrence of NLs provided significant prognostic value and should be considered when evaluating treatment response to [177Lu]Lu-PSMA therapy. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a LuPSMA |2 Other |
| 650 | _ | 7 | |a PSMA PET |2 Other |
| 650 | _ | 7 | |a RECIP |2 Other |
| 650 | _ | 7 | |a metastatic castration-resistant prostate cancer |2 Other |
| 650 | _ | 7 | |a radiopharmaceutical therapy |2 Other |
| 650 | _ | 7 | |a response evaluation |2 Other |
| 700 | 1 | _ | |a Farolfi, Andrea |b 1 |
| 700 | 1 | _ | |a Rauscher, Isabel |b 2 |
| 700 | 1 | _ | |a Haghighatian, Mahan |b 3 |
| 700 | 1 | _ | |a Mercier, Alexis |b 4 |
| 700 | 1 | _ | |a Fendler, Wolfgang P |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Hadaschik, Boris |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Herrmann, Ken |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Solnes, Lilja B |b 8 |
| 700 | 1 | _ | |a Rettig, Matthew |b 9 |
| 700 | 1 | _ | |a Weber, Manuel |0 P:(DE-He78)44ee3b9a92e23f6844eefca1ab816eb9 |b 10 |u dkfz |
| 700 | 1 | _ | |a Czernin, Johannes |b 11 |
| 700 | 1 | _ | |a Calais, Jeremie |b 12 |
| 700 | 1 | _ | |a Benz, Matthias R |b 13 |
| 700 | 1 | _ | |a Eiber, Matthias |b 14 |
| 700 | 1 | _ | |a Gafita, Andrei |b 15 |
| 773 | _ | _ | |a 10.2967/jnumed.125.270239 |g p. jnumed.125.270239 - |0 PERI:(DE-600)2040222-3 |p nn |t Journal of nuclear medicine |v nn |y 2025 |x 0097-9058 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:305583 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)44ee3b9a92e23f6844eefca1ab816eb9 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-01 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-01 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|